Core Insights - Bionano Genomics showcased the expanding role of optical genome mapping (OGM) in genetic disease research at the ASHG conference, emphasizing its effectiveness in detecting structural variants (SVs) related to various genetic conditions [1][2][3] Group 1: Event Participation - Bionano Genomics participated in the ASHG conference held from October 14–18, 2025, in Boston, highlighting the potential of OGM in genetic research [1] - The conference featured nine studies that demonstrated OGM's ability to detect novel SVs that traditional techniques may miss, underscoring its value in complex genetic conditions [2] Group 2: Scientific Contributions - Presentations included studies on OGM's application in various conditions, such as Duchenne Muscular Dystrophy and facioscapulohumeral muscular dystrophy (FSHD), showcasing its unique capabilities [6] - The studies presented at ASHG 2025 illustrate OGM's potential to provide deeper insights into complex genetic conditions, reinforcing its transformative role in genetic research [3] Group 3: Company Mission and Offerings - Bionano aims to transform genome analysis through OGM solutions, diagnostic services, and software, catering to basic, translational, and clinical research applications [5] - The company also provides OGM-based diagnostic testing services through its subsidiary, Lineagen, Inc. [7]